Thus, stimulating downstream signaling of DOCK3 in combination with suppression of the ROCK/CRMP2 and ROCK/LIM kinase/cofilin pathways may be available for neurodegenerative diseases, such as glaucoma4,29–31. This evidence concerns the gene DPYSL2 and neurodegenerative disease.